Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients

SIMPLE SUMMARY: Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in non-small cell lung cancer (NSCLC). A total of 172 patients with advanced NSCLC treated with osimertinib following front...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yan-Jei, Chang, John Wen-Cheng, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Fang, Yueh-Fu, Hsu, Ping-Chih, Wu, Chiao-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600420/
https://www.ncbi.nlm.nih.gov/pubmed/36291877
http://dx.doi.org/10.3390/cancers14205095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600420/
https://www.ncbi.nlm.nih.gov/pubmed/36291877
http://dx.doi.org/10.3390/cancers14205095

Ejemplares similares